Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018087641) COMPOSITIONS AND METHODS FOR INHIBITING GROWTH OF ACSL4-OVEREXPRESSING TUMORS
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

CLAIMS

1- A pharmaceutical combination for inhibiting growth of a tumor overexpressing ACSL4, comprising a first and a second dosage forms, wherein: i) the first dosage form comprises an ACSL4 inhibitor; and ii) the second dosage form comprises a chemotherapeutic agent.

2- A pharmaceutical composition according to claim 1, wherein the ACSL4 inhibitor is present in sub-therapeutically effective amounts

3- A pharmaceutical composition according to claim 1, wherein the chemotherapeutic agent is present in sub-therapeutically effective amounts.

4- The pharmaceutical combination according to claim 1, wherein the tumor overexpressing ACSL4 is selected from the group consisting of colon carcinoma, hepatocellular carcinoma, prostate cancer, breast cancer and triple negative breast cancer (TNBC).

5- The pharmaceutical combination according to claim 1, wherein the ACSL4 inhibitor is selected from the group of Triacsin C, and rosiglitazone, and ii) the chemotherapeutic agent is selected from doxorubicin, paclitaxel and docetaxel.

6- The pharmaceutical combination according to claim 5 wherein the ACSL4 inhibitor is Triacsin C, and the chemotherapeutic agent is selected from paclitaxel and docetaxel.

7- The pharmaceutical combination according to claim 5 wherein the ACSL4 inhibitor is Triacsin C, and the chemotherapeutic agent is doxorubicin.

8- The pharmaceutical combination according to claim 5 wherein the ACSL4 inhibitor is rosiglitazone, and the chemotherapeutic agent is selected from paclitaxel and docetaxel.

9- The pharmaceutical combination according to claim 5 wherein the ACSL4 inhibitor is rosiglitazone, and the chemotherapeutic agent is doxorubicin.

10- A pharmaceutical composition for inhibiting growth of a tumor overexpressing ACSL4, comprising: i) an ACSL4 inhibitor; and ii) a chemotherapeutic agent.

11- A pharmaceutical composition according to claim 10, wherein the ACSL4 inhibitor is present in sub-therapeutically effective amounts.

12- A pharmaceutical composition according to claim 10, wherein the chemotherapeutic agent is present in sub-therapeutically effective amounts.

13- The pharmaceutical composition according to claim 10, wherein the tumor overexpressing ACSL4 is selected from the group consisting of colon carcinoma, hepatocellular carcinoma, prostate cancer, breast cancer and triple negative breast cancer (TNBC).

14- The pharmaceutical composition according to claim 10, wherein the ACSL4 inhibitor is selected from the group of Triacsin C, and rosiglitazone, and ii) the chemotherapeutic agent is selected from doxorubicin, paclitaxel and docetaxel.

15- The pharmaceutical composition according to claim 14, wherein the ACSL4 inhibitor is Triacsin C, and the chemotherapeutic agent is selected from paclitaxel and docetaxel.

16- The pharmaceutical composition according to claim 14, wherein the ACSL4 inhibitor is Triacsin C, and the chemotherapeutic agent is doxorubicin.

17- The pharmaceutical composition according to claim 14, wherein the ACSL4 inhibitor is rosiglitazone, and the chemotherapeutic agent is selected from paclitaxel and docetaxel.

18- The pharmaceutical composition according to claim 14, wherein the ACSL4 inhibitor is rosiglitazone, and the chemotherapeutic agent is doxorubicin.

19- A method for treating a patient having a tumor overexpressing ACSL4, the method comprising administering to the patient: i) a dosage form of a first component being an ACSL4 inhibitor; and ii) a dosage form of a second component being a chemotherapeutic agent.

20- The method according to claim 19, wherein the ACSL4 inhibitor is present in sub-therapeutically effective amounts

21- The method according to claim 19, wherein the chemotherapeutic is present in sub-therapeutically effective amounts.

22- The method according to claim 19, wherein the tumor is colon carcinoma, hepatocellular carcinoma, prostate cancer, breast cancer or triple negative breast cancer (TNBC).

23- The method according to claim 19, wherein the tumor is metastatic.

24- The method according to claim 22, wherein the triple negative breast cancer (TNBC) is metastatic.

25- The method according to claim 19, wherein the ACSL4 inhibitor is selected from the group of Triacsin C, and rosiglitazone, and ii) the chemotherapeutic agent is selected from doxorubicin, paclitaxel and docetaxel.

26- The method according to claim 25, wherein the ACSL4 inhibitor is Triacsin C, and the chemotherapeutic agent is selected from paclitaxel and docetaxel.

27- The method according to claim 25, wherein the ACSL4 inhibitor is Triacsin C, and the chemotherapeutic agent is doxorubicin.

28- The method according to claim 25, wherein the ACSL4 inhibitor is rosiglitazone, and the chemotherapeutic agent is selected from paclitaxel and docetaxel.

29- The method according to claim 25, wherein the ACSL4 inhibitor is rosiglitazone, and the chemotherapeutic agent is doxorubicin.

30- The method according to claim 19, wherein the ACSL4 inhibitor is administered prior, or during administering the chemotherapeutic agent.